Laurion Capital Management LP Eli Lilly & CO Call Options Transaction History

Laurion Capital Management LP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Nov 15, 2021	BUY	$221.6 - $272.71 $2.06 Million - $2.54 Million	9,300 New	9,300 $2.15 Million
Q2 2020 Aug 14, 2020	SELL	$136.42 - $164.18 $477,469 - $574,630	-3,500 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$119.05 - $147.35 $416,675 - $515,725	3,500 New	3,500 $486,000
Q4 2019 Feb 13, 2020	SELL	$106.92 - $132.43 $37.4 Million - $46.4 Million	-350,000 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$106.79 - $116.16 $9.55 Million - $10.4 Million	89,400 Added 34.31%	350,000 $39.1 Million
Q3 2018 Nov 13, 2018	BUY	$85.86 - $107.31 $18.9 Million - $23.7 Million	220,600 Added 551.5%	260,600 $28 Million
Q3 2017 Nov 13, 2017	BUY	$77.07 - $85.54 $3.08 Million - $3.42 Million	40,000	40,000 $3.42 Million

4,011

751M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.